These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 24553930)

  • 1. A sensitive aβ oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid.
    Savage MJ; Kalinina J; Wolfe A; Tugusheva K; Korn R; Cash-Mason T; Maxwell JW; Hatcher NG; Haugabook SJ; Wu G; Howell BJ; Renger JJ; Shughrue PJ; McCampbell A
    J Neurosci; 2014 Feb; 34(8):2884-97. PubMed ID: 24553930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S
    Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF.
    Yang T; Hong S; O'Malley T; Sperling RA; Walsh DM; Selkoe DJ
    Alzheimers Dement; 2013 Mar; 9(2):99-112. PubMed ID: 23375565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amyloid-β oligomers relate to cognitive decline in Alzheimer's disease.
    Jongbloed W; Bruggink KA; Kester MI; Visser PJ; Scheltens P; Blankenstein MA; Verbeek MM; Teunissen CE; Veerhuis R
    J Alzheimers Dis; 2015; 45(1):35-43. PubMed ID: 25547634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease.
    Santos AN; Ewers M; Minthon L; Simm A; Silber RE; Blennow K; Prvulovic D; Hansson O; Hampel H
    J Alzheimers Dis; 2012; 29(1):171-6. PubMed ID: 22214781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The amyloid-β oligomer count in cerebrospinal fluid is a biomarker for Alzheimer's disease.
    Wang-Dietrich L; Funke SA; Kühbach K; Wang K; Besmehn A; Willbold S; Cinar Y; Bannach O; Birkmann E; Willbold D
    J Alzheimers Dis; 2013; 34(4):985-94. PubMed ID: 23313925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid-β oligomer detection by ELISA in cerebrospinal fluid and brain tissue.
    Bruggink KA; Jongbloed W; Biemans EA; Veerhuis R; Claassen JA; Kuiperij HB; Verbeek MM
    Anal Biochem; 2013 Feb; 433(2):112-20. PubMed ID: 23022042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies.
    van Steenoven I; van der Flier WM; Scheltens P; Teunissen CE; Lemstra AW
    Alzheimers Res Ther; 2019 Oct; 11(1):83. PubMed ID: 31601267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Luminex assay detects amyloid β oligomers in Alzheimer's disease cerebrospinal fluid.
    Herskovits AZ; Locascio JJ; Peskind ER; Li G; Hyman BT
    PLoS One; 2013; 8(7):e67898. PubMed ID: 23844122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification.
    Izzo NJ; Yuede CM; LaBarbera KM; Limegrover CS; Rehak C; Yurko R; Waybright L; Look G; Rishton G; Safferstein H; Hamby ME; Williams C; Sadlek K; Edwards HM; Davis CS; Grundman M; Schneider LS; DeKosky ST; Chelsky D; Pike I; Henstridge C; Blennow K; Zetterberg H; LeVine H; Spires-Jones TL; Cirrito JR; Catalano SM
    Alzheimers Dement; 2021 Aug; 17(8):1365-1382. PubMed ID: 33559354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isobaric Quantification of Cerebrospinal Fluid Amyloid-β Peptides in Alzheimer's Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration.
    Rogeberg M; Almdahl IS; Wettergreen M; Nilsson LN; Fladby T
    J Proteome Res; 2015 Nov; 14(11):4834-43. PubMed ID: 26452689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of Amyloid-beta aggregates in body fluids: a suitable method for early diagnosis of Alzheimer's disease?
    Funke SA; Birkmann E; Willbold D
    Curr Alzheimer Res; 2009 Jun; 6(3):285-9. PubMed ID: 19519310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reappraisal of Aβ40 and Aβ42 Peptides Measurements in Cerebrospinal Fluid of Patients with Alzheimer's Disease.
    Fiorini M; Bongianni M; Benedetti MD; Monaco S; Zanusso G
    J Alzheimers Dis; 2018; 66(1):219-227. PubMed ID: 30282368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid-β 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays.
    Lewczuk P; Lelental N; Spitzer P; Maler JM; Kornhuber J
    J Alzheimers Dis; 2015; 43(1):183-91. PubMed ID: 25079805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients.
    Fukumoto H; Tokuda T; Kasai T; Ishigami N; Hidaka H; Kondo M; Allsop D; Nakagawa M
    FASEB J; 2010 Aug; 24(8):2716-26. PubMed ID: 20339023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia.
    Spies PE; Slats D; Sjögren JM; Kremer BP; Verhey FR; Rikkert MG; Verbeek MM
    Curr Alzheimer Res; 2010 Aug; 7(5):470-6. PubMed ID: 20043812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of specific amyloid-β oligomers with tau in cerebrospinal fluid from cognitively normal older adults.
    Handoko M; Grant M; Kuskowski M; Zahs KR; Wallin A; Blennow K; Ashe KH
    JAMA Neurol; 2013 May; 70(5):594-9. PubMed ID: 23479202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain.
    Hey JA; Kocis P; Hort J; Abushakra S; Power A; Vyhnálek M; Yu JY; Tolar M
    CNS Drugs; 2018 Sep; 32(9):849-861. PubMed ID: 30076539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SOBA: Development and testing of a soluble oligomer binding assay for detection of amyloidogenic toxic oligomers.
    Shea D; Colasurdo E; Smith A; Paschall C; Jayadev S; Keene CD; Galasko D; Ko A; Li G; Peskind E; Daggett V
    Proc Natl Acad Sci U S A; 2022 Dec; 119(50):e2213157119. PubMed ID: 36490316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.